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Abstract
In the human prion disease Creutzfeldt-Jakob disease (CJD), different CJD neuropathological subtypes are defined
by the presence in normal prion protein (PrPC) of a methionine or valine at residue 129, by the molecular mass of
the infectious prion protein PrPSc, by the pattern of PrPSc deposition, and by the distribution of spongiform change
in the brain. Heterozygous cases of CJD potentially add another layer of complexity to defining CJD subtypes since
PrPSc can have either a methionine (PrPSc-M129) or valine (PrPSc-V129) at residue 129. We have recently
demonstrated that the relative amount of PrPSc-M129 versus PrPSc-V129, i.e. the PrPSc allotype ratio, varies between
heterozygous CJD cases. In order to determine if differences in PrPSc allotype correlated with different disease
phenotypes, we have inoculated 10 cases of heterozygous CJD (7 sporadic and 3 iatrogenic) into two transgenic
mouse lines overexpressing PrPC with a methionine at codon 129. In one case, brain-region specific differences in
PrPSc allotype appeared to correlate with differences in prion disease transmission and phenotype. In the other 9
cases inoculated, the presence of PrPSc-V129 was associated with plaque formation but differences in PrPSc allotype
did not consistently correlate with disease incubation time or neuropathology. Thus, while the PrPSc allotype ratio
may contribute to diverse prion phenotypes within a single brain, it does not appear to be a primary determinative
factor of disease phenotype.
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Introduction
Prion diseases are fatal, transmissible neurodegenerative
diseases of mammals that are associated with the mis-
folding of a normally protease-sensitive and soluble pro-
tein called prion protein or PrPC, into a partially
protease-resistant, insoluble and infectious form termed
PrPSc [18]. Accumulation of PrPSc in the brain over time,
as large amyloid or non-amyloid aggregates, eventually
leads to clinical prion disease and death. In humans,
prion diseases can be hereditary, sporadic, or acquired.
In hereditary prion diseases, mutations in the prion
protein (PRNP) gene are associated with different types
of prion disease such as Gerstmann-Sträussler-Scheinker
syndrome, fatal familial insomnia, and genetic
Creutzfeldt-Jakob disease [26]. Sporadic Creutzfeldt-
Jakob disease (sCJD), which is thought to arise as the re-
sult of spontaneous misfolding of PrPC in the brain into
infectious PrPSc, is the most common form of human
prion disease and occurs at an incidence of approxi-
mately1–2 cases per million people worldwide. Acquired
forms of prion disease can result from the ingestion of
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prion contaminated tissue, as was the case with variant
CJD which has been linked to ingestion of bovine spongi-
form encephalopathy (BSE) contaminated products, and
kuru, which was the result of the cannibalistic practices of
the Fore tribe in New Guinea. They can also result from
exposure to prion contaminated medical instruments, de-
vices or products such as dura mater grafts, pituitary gland
derived human growth hormone, and human blood and
blood products. Collectively, these latter forms of acquired
prion disease are known as iatrogenic CJD (iCJD) [22].
In humans, there is a naturally occurring polymorph-
ism in PRNP represented by either a methionine or
valine at codon 129 which helps to define the neuro-
pathological subtype of sCJD [25, 30, 31]. CJD subtypes
are also classified according to the size of PrPSc follow-
ing protease digestion [30–32, 41]. Type 1 CJD is associ-
ated with a PrPSc molecule of 21 kDa while Type 2 CJD
is associated with a 19 kDa PrPSc molecule [30, 31].
There are therefore 6 potential subtypes of sCJD based
on the possible combinations of PrPSc size and PRNP
genotype: MM1, MM2, VV1, VV2, MV1, and MV2. CJD
subtype can be further defined by different patterns of
pathology (i.e. spongiform change and neuronal loss)
and PrPSc deposition in the brain [3, 30, 31, 33], and by
transmission properties into non-human primates [8] or
transgenic mice expressing human PrPC [1, 2, 5, 9, 13,
23, 44]. Based on all of these criteria, there are currently
believed to be 6 major subtypes or strains of sCJD (in
order of frequency): MM1/MV1, VV2, MV2K (i.e. Type
2 PrPSc with the “K” designating kuru-type plaques),
MM2T (thalamic), MM2C (cortical), and VV1 [3].
Within CJD subtypes, there can be atypical disease
presentations as well as variation in neuropathological
phenotypes [3, 33, 34]. The molecular mechanisms
underlying this variability are unclear but may be ex-
plained by the fact that multiple PrPSc types can co-
occur within different CJD subtypes [10, 19, 24, 31, 34,
36, 41]. Approximately one-third of sCJD cases show the
co-presence of Type 1 and Type 2 PrPSc within the
same, or different, regions of a single brain [10, 34, 36].
For example, the most common mixed CJD type, MV1 +
2C, refers to cases with Type 1 PrPSc that also have cor-
tical pathology (designated by the C) and focal Type 2
PrPSc deposition [33]. Thus, within a single subtype of
sCJD, prions with different conformations may be
present that could influence disease progression and
pathogenesis in unpredictable ways.
The prion protein allotype may also be influencing dis-
ease phenotype. It is known that heterozygosity in PrPC
at codon 129 is associated with resistance to sCJD, as
well as later disease onset and longer disease duration in
kuru [11]. In sCJD, a valine at residue 129 has been asso-
ciated with plaque formation and a longer clinical dis-
ease course [21] while a methionine at residue 129 has
been associated with a more synaptic pattern of PrPSc
deposition and a shorter clinical course [21]. Thus, in
heterozygous cases of sCJD where both PrPSc with a
methionine (PrPSc-M129) and PrPSc with a valine
(PrPSc-V129) may be present, the relative amounts of
each allotype (i.e. the PrPSc allotype ratio), might influ-
ence disease pathogenesis. Indeed, there is considerable
phenotypic variation within heterozygous cases of MV2
sCJD [3, 23] which might be explained if the PrPSc allo-
type ratio influenced disease parameters such as disease
incubation time and neuropathology.
Transmission of MV heterozygous cases of CJD into
transgenic mice expressing human PrPC would help to
further elucidate the role of PrPSc allotype on disease
phenotype. Unfortunately, only a few such studies have
been published [1, 2, 5, 20, 23, 25, 44] and most involved
the inoculation of only one or two cases of heterozygous
sCJD [1, 2, 5, 20, 23]. In one study, inoculation of MV
CJD into transgenic mice expressing human PrPC-M129
resulted in either short or long incubation times, leading
the authors to hypothesize that incubation time might
reflect differences in the propagation of PrPSc-M129 ver-
sus PrPSc-V129 [2]. However, since it is only recently
that mass spectrometry has been used to determine
PrPSc allotype in MV heterozygous cases of CJD [28],
the PrPSc allotype ratio of the MV heterozygous CJD
cases transmitted into transgenic mice to date remains
unknown. Thus, there is no direct evidence for what ef-
fect PrPSc allotype may have on prion disease incubation
time and phenotype.
We have recently shown that the PrPSc allotype ra-
tio is variable in MV1 and MV2 cases of sCJD but
somewhat less variable in cases of MV2K iCJD in the
United Kingdom (UK) [28] that were the result of ex-
posure to prion contaminated human growth hor-
mone derived from cadavers. In particular, our
analysis of four MV2 sCJD cases showed that statisti-
cally significant differences in the amount of PrPSc-
M129 isolated from different brain regions of a single
patient were associated with brain region-specific dif-
ferences in PrPSc deposition [28]. In order to under-
stand the potential contribution of the PrPSc allotype
to disease transmission and phenotype in heterozy-
gous CJD subtypes, we inoculated 10 cases of MV
heterozygous sCJD or iCJD into transgenic mice over-
expressing human PrPC-M129. In one case, brain-
region specific differences in PrPSc allotype appeared
to correlate with differences in prion disease trans-
mission and phenotype. Differences in PrPSc allotype
did not consistently correlate with disease incubation
times in the other 9 cases but the presence of PrPSc-
V129 was associated with plaque deposition. Thus,
while our data are consistent with differences in the
PrPSc allotype contributing to variable phenotypes in
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MV heterozygous cases of CJD, it is not the primary
determinant of the final disease phenotype.
Materials and methods
Ethics statement
Human brain samples were obtained either from the
National CJD Research & Surveillance Unit Brain and
Tissue Bank, which is part of the MRC Edinburgh Brain
& Tissue Bank (Edinburgh Brain Bank 16-ES-0084), UK,
or from the University of Verona, Italy. These latter tis-
sues were obtained at autopsy and sent to the Neuro-
pathology Unit at the University of Verona for statutory
definite diagnosis of CJD. Ethical approval for the acqui-
sition and use of post-mortem human CJD brain
samples was obtained from the National Institutes of
Health (NIH) Office of Human Subject Research (Ex-
empt #11763 and #12725) and no patient identifiable
data was transferred to the NIH. The neuropathological
and biochemical characteristics of all samples inoculated
have been previously described [28].
Inoculation of tg66 and tgRM mice
The animal experimental protocol was reviewed and ap-
proved by the Rocky Mountain Laboratories Animal
Care and Use Committee. This study was carried out in
strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health.
Tg66 and tgRM mice over-expressing human PrPC-
M129 [37] were infected by injecting 50 μl of brain hom-
ogenate from confirmed CJD cases via the intracerebral
route using a 27-gauge ½ inch needle. All brain homoge-
nates were prepared using the following procedure. A 10%
weight per volume (w/v) solution was prepared from fro-
zen brain tissue in sterile phosphate buffered saline by
homogenizing with 2 × 30 s bursts using a Minibeadbeater
(Biospec Products). Each sample was sonicated for 2 mins,
then further diluted to 1% w/v in phosphate buffered bal-
anced salts solution (PBBS; 1.5 mM potassium phosphate
monobasic, 6.6 mM sodium phosphate dibasic anhydrous,
1.3 mM calcium chloride anhydrous, 4.3 mM potassium
chloride, 123.2mM sodium chloride, 1 μM magnesium
chloride 6-hydrate, 0.8 μM magnesium sulfate 7- hydrate,
1% phenol red, and 5.6 mM glucose) plus 2% fetal bovine
serum. Samples were vortexed and then spun for 1min at
3000 rpm immediately prior to injection. The titer of the
CJD MM1 control was 2 × 105.4 ID50/g brain tissue.
Mice were monitored twice weekly for signs of disease.
Once early clinical signs appeared, such as aberrant nest-
ing and ruffled fur, mice were checked daily. Late neuro-
logical clinical signs included kyphosis, somnolence,
reluctance or inability to move normally, ataxia, and vis-
ible weight loss. When mice displayed these late clinical
signs, they were euthanized using isoflurane in a jar in a
scavenger hood. Brains were removed, cut in half
along the sagittal midline, and one half was frozen in
liquid nitrogen for use in western blot while the other
half was placed into 10% normal buffered formalin
(NBF) for fixation prior to immunohistochemical
analysis.
Real time quaking induced conversion (RT-QuIC) endpoint
titration assay
Brain homogenates were serially diluted (10-fold dilution
series from 10− 3 to 10− 10) in RT-QuIC reaction solution
(0.1% sodium dodecyl sulfate (SDS), 1x N-2 supplement
(ThermoFisher) and 1x phosphate buffered saline PBS;
130 mM NaCl, 10 mM PO4, pH 7.4). Prion seeding activ-
ity for each dilution was measured in a 96-well plate by
adding 2 μL diluted brain homogenate to 98 μL RT-
QuIC reaction solution to give final concentrations of
0.1 mg/ml bacterially derived and purified recombinant
hamster PrPC (amino acid residues 90–231) [29], 10 mM
phosphate buffer pH 7.4, 10 μM thioflavin T (ThT), 300
mM NaCl, 1 mM ethylenediaminetetraacetic acid
(EDTA) and 0.002% SDS. Four technical replicate reac-
tion wells were prepared for each dilution. The plates
were then shaken in a temperature-controlled fluores-
cence plate reader (BMG FLUOstar) at 50 °C with cycles
of 1 min double orbital shaking at 700 rpm and 1min of
rest. ThT fluorescence was measured at 45-min inter-
vals. For each sample, the assay was repeated three times
for a total of 12 replicate wells per dilution. The prion
seeding dose (SD), defined as the dilution in an endpoint
RT-QuIC dilution assay at which 50% of the wells are
ThT positive [45], was calculated using the Spearman-
Kärber method [17] and reported as SD50/g of brain
homogenate.
Immunohistochemistry
Formalin fixed tissue was processed and embedded in paraf-
fin. Sections (5 μm) were cut using a standard Leica micro-
tome, placed on positively charged glass slides, and air-dried
overnight at room temperature. Prior to deparaffinization
slides were heated in an oven at 60 °C for 20min. The brain
tissue was deparaffinized in Pro-Par clearant (Anatech In-
novator), followed by rehydration in decreasing concentra-
tions of ethanol with a final rinse in distilled water. Slides
were immersed in 10mM citrate buffer (pH 6.0), placed in a
Biocare decloaking chamber, and treated at 120 °C at 20 lb./
in2 pressure for 20min. After cooling, the slides were stained
using DABMap kit and hematoxylin counterstain on an au-
tomated Discovery XT staining system (Ventana Medical
Systems). The primary antibody was the anti-PrP mouse
monoclonal antibody 3F4 conjugated to biotin (Covance) di-
luted 1:50 in Ventana antibody dilution buffer (Ventana
Medical Systems) with an incubation time of 60min.
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Other stains
The presence of amyloid plaques was confirmed by
staining deparaffinized sections with the amyloid dye
Thioflavin S (ThioS) as previously described [35]. Hamo-
toxylin and eosin (H&E) staining was performed by hand
on deparaffinized slides using Shandon Instant Hemo-
toxylin and Eosin (Thermo Scientific) according to the
manufacturer’s instructions.
SDS-PAGE and Western blotting
Brain halves from tg66 and tgRM mice were homoge-
nized in PBS to 20% (w/v) with 2 × 30 s bursts using a
Minibeadbeater. Tris-HCL (pH 8.5), sodium deoxycho-
late , and Triton X-100 were added to the homogenate
to give final concentrations of 0.1 M, 1%, and 1%, re-
spectively. Samples were protease treated by adding pro-
teinase K (PK) to a final concentration of 63.3 μg/ml
followed by incubation for 30 min at 37 °C in a circulat-
ing water bath. The PK was then neutralized by adding
0.1M phenylmethylsulfonyl fluoride (PMSF) to a final
concentration of 0.01M. For each sample, 17.2 μl of
Novex NuPage lithium dodecyl sulfate (LDS) 4X sample
loading buffer (Life Technologies) was pre-diluted to 2X,
17.2 μl of sample was added, and the sample boiled for
3 min. Samples were loaded onto a 15 well, 1.5 mm
NuPage 4–20% Bis-Tris gradient gel (Invitrogen) and
run for 75 min at constant voltage (120 V).
After electrophoresis, samples were transferred to
polyvinylidene difluoride (PVDF) membrane (Millipore)
at 37 V overnight at 4o C in Towbin’s buffer (0.25M
Tris, 1.92M Glycine, 0.01% SDS, 20% methanol). Mem-
branes were blocked with Blotto (5% milk in Tris buff-
ered saline plus Tween (TBST): 137mM NaCl, 2.7 mM
KCl, 19 mM Tris base, 0.1% Tween 20) for 1.5 h. The
membrane was developed using the anti-PrP mouse
monoclonal antibody 3F4 conjugated to biotin (Covance)
at a 1:10,000 dilution for 1.5 h at room temperature on a
shaking platform. Following a 30 min period of 3 to 4
washes in TBST, the membrane was incubated for 1 h at
room temperature in a 1:250,000 dilution in TBST of
streptavidin-horseradish peroxidase (SA-HRP, Cell
Signaling Technology). The wash step above was re-
peated and the membranes rinsed in distilled water be-
fore being developed with SuperSignal West Femto
Maximum Sensitivity Substrate (Thermo Scientific) for
detection on X-ray film.
Statistics
The unpaired student’s t-text, Tukey’s multiple compari-
sons test, linear regression, and sample mean and stand-
ard deviation were all calculated using the GraphPad
Prism software package (version 8.2).
Results
Transmission of MV heterozygous cases of sCJD and iCJD
into transgenic mice overexpressing human PrPC
We have previously shown that variability in the PrPSc allo-
type ratio can be associated with different types of PrPSc de-
position within the brain [28]. In order to determine
whether or not the PrPSc allotype ratio influenced the trans-
mission properties of MV heterozygous cases of CJD, brain
samples from 10 cases of codon 129 heterozygous sCJD
(n = 7) or iCJD (n = 3) whose prion disease phenotype had
been previously characterized both neuropathologically and
biochemically [28], were tested for their ability to transmit
disease to transgenic mice overexpressing human PrPC-
M129. The cases were selected based upon the amount of
PrPSc-M129 present in the sample, which ranged from 100
to 29% of the total PrPSc and represented 4 different neuro-
pathological subtypes of CJD (Tables 1 and 2). All cases
had detectable, but variable, levels of PrPSc as determined
by mass spectroscopy (Table 1 and [28]) and western blot
[28]. Using the RT-QuIC endpoint titration assay, most of
the cases had similar prion seeding activities (Table 1) sug-
gesting that they had similar levels of prion infectivity [45].
Brain homogenate samples from the cerebral cortex
(CC) or the cerebellar cortex (CbC) were inoculated
intracranially into two different strains of transgenic
mice over-expressing human PrPC-M129 [37], tgRM and
tg66. Since both mouse strains are homozygous for
PrPC-M129, we hypothesized that they would be more
susceptible to heterozygous CJD isolates containing
Table 1 PrPSc abundance and prion seeding activity in CJD
brain homogenate samples inoculated into transgenic mice
Case #a Subtypea PrPSc (SpC)b SD50/g
c
Control MM1 ND > 5 × 109
3 MV1 + 2C 280 ± 103 5 × 109
4 MV1 + 2C 48 ± 9 9 × 107
9 CC MV2K + 2C 56 ± 12 8.9 × 1010
9 CbC MV2K + 2C 126 ± 15 2.8 × 1010
12 MV2K + 2C 90 ± 4 1.6 × 109
19 (iCJD) MV2K 133 ± 19 3.5 × 1011
10 MV2K 175 ± 19 1.2 × 1011
20 (iCJD) MV2K 171 + 44 1.6 × 1011
7 MV2K 581 ± 89 2.8 × 1011
18 (iCJD) MV2K 65 ± 7 2.8 × 1011
11 MV2C 290 ± 9 3.4 × 1010
aNeuropathological subtype of cases originally described in [28]. All cases are
sCJD except where noted as iCJD. CC cerebral cortex, CbC cerebellar cortex
bSpC spectral counts. Total number of PrPSc peptides as determined by mass
spectrometry of phosphotungstic acid precipitated CJD brain material For
mean + standard deviation in previous sentence, please underline the + sign.
are adapted from [28]
cSD50/g = prion seeding doses (SD) yielding 50% positive wells in replicate RT-
QuIC reactions per 1 g of MV brain homogenate [45]. Values were calculated
from 3 independent end-point titration experiments
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higher levels of PrPSc-M129. Transmission results are
summarized in Table 2 and survival curves are shown in
Fig. 1. For both mouse strains, the majority of cases in-
oculated caused clinical disease in at least some of the
mice. As expected, disease incubation times were gener-
ally shorter in the tg66 mice which express higher levels
of human PrPC-M129 when compared to the tgRM mice
[38]. Only two samples, case 4 and the CC sample from
case 9, failed to cause any clinical disease within the life-
time of the host, although neuropathology and PrPSc de-
position were observed in a few mice suggesting that
clinical disease may have eventually developed in those
animals.
The amount of PrPSc-M129 does not correlate with
disease incubation time in tg66 or tgRM mice
Consistent with previous transmission studies of hetero-
zygous CJD cases [1, 2, 5, 23, 25], extended disease incu-
bation times of more than 400 days were observed for
most of the samples tested, although in many instances
clinical signs of disease were observed in only a percent-
age of the total mice inoculated (Fig. 1 and Table 2).
The exceptions were cases 3, 18, and 19 which caused
clinical disease with incubation times of less than 400
days. In cases 3 and 19, PrPSc-M129 comprised 100 and
66%, respectively, of the total PrPSc while in case 18
PrPSc-M129 comprised only 36% of the total PrPSc.
Thus, our transmission results would appear to be in-
consistent with higher levels of PrPSc-M129 generally
being predictive of faster disease incubation times.
Indeed, two other MV heterozygous CJD samples with
greater than 80% PrPSc-M129 either did not cause dis-
ease (case 9, CC sample) or caused disease in only a mi-
nority of tg66 mice inoculated (case 11). A linear
regression analysis comparing clinical disease incubation
times to PrPSc-M129 levels confirmed that, for both
mouse strains, there was a poor correlation between the
amount of PrPSc-M129 in the heterozygous CJD sample
and clinical disease incubation time (Fig. 2a). In addition,
we found no linear correlation of total PrPSc levels in the
brain with clinical disease incubation time in either tg66
or tgRM mice (Fig. 2b). Thus, our data suggest that the
observed differences in disease incubation time were un-
related to either PrPSc-M129 or total PrPSc levels.
CJD PrPSc type is not maintained following transmission
into tg66 and tgRM mice
We next looked at the size of PrPSc deposited in the
brain. Previous studies have shown that inoculation of
MM1, MV1, and MV2 cases of CJD into mice homozy-
gous for PrPC-M129 always resulted in the deposition of
Type 1 PrPSc in the brains of recipient mice [5, 23, 25].
We also found that Type 1 PrPSc accumulated in tg66
and tgRM mice inoculated with both the MV1 (Fig. 3)
and MV2K (Fig. 4) CJD subtypes. However, for two sam-
ples that did not transmit well to mice, cases 11 and 9
CC, Type 2 PrPSc accumulated in at least one of the two
recipient mouse lines inoculated (Fig. 3). While these
data are consistent with Type 2 PrPSc inhibiting disease,
it is important to note that accumulation of Type 1
Table 2 Transmission of sCJD and iCJD with variable PrPSc allotypes into tg66 and tgRM mice overexpressing human PrPC-M129
tg66 tgRM
Case #a Subtypeb PrPSc-M129c DPId Clin/totale DPId Clin/totale
Control MM1 100 187 ± 13 9/9 211 ± 11 8/8
3 MV1 + 2C 100 ± 0**** 196 ± 19 8/8 218 ± 13 7/8
4 MV1 + 2C 34 ± 5 > 611 0/7 > 651 0/6
9 (CC) MV2K + 2C 82 ± 8** > 502 0/5 > 662 0/7
9 (CbC) MV2K + 2C 33 ± 8 488 ± 17 5/5 519 ± 26 2/4
12 MV2K + 2C 29 ± 20 497 ± 132 2/5 471 1/7
19 (iCJD) MV2K 66 ± 4*** 184 ± 2 3/3 214 ± 9 7/7
10 MV2K 43 ± 2 407 ± 36 7/7 503 ± 54 5/6
20 (iCJD) MV2K 39 ± 6 482 ± 34 2/7 373 1/5
7 MV2K 38 ± 18 398 ± 13 6/6 448 ± 18 4/5
18 (iCJD) MV2K 36 ± 5 238 ± 17 5/8 296 ± 46 4/7
11 MV2C 85 ± 1 401 ± 21 2/8 > 790 0/8
aNeuropathological subtype of cases originally described in [28]. All cases are sCJD except where noted as iCJD. CB cerebellar cortex, CC cerebral cortex
bCases originally described in [28]. MV2K = CJD subtype MV2 with kuru (K) plaques; 2C = Type 2 PrPSc in the cortex
cPercentage of PrPSc in the inoculum which is PrPSc-M129 shown as mean + standard deviation. Data adapted from [28]. **** p = 0.0001 versus case 4 by unpaired
student’s t-test; ***p = 0.02 versus case 10, 0.007 versus case 20, 0.009 versus case 7, and 0.003 versus case 18 using Tukey’s multiple comparisons test; ** p = 0.01
versus case 9 (CbC) and 12 using Tukey’s multiple comparisons test
dDPI =mean days post-infection + standard deviation
eNumber of mice with clinical disease over total number of mice inoculated. Intercurrent deaths are not included
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PrPSc was also observed in cases that transmitted poorly
(Fig. 3a and Fig. 4, see cases 4 and 20). Thus, our results
suggest that the type of PrPSc deposited in the brain does
not appear to correlate well with prolonged disease incu-
bation times and/or lack of clinical disease. Moreover,
they support a previous study [5] which suggested that
the final PrPSc type in recipient mice is not determined
solely by the PrPSc type in the inoculum but rather by
interactions between the prion strain inoculated and the
host.
PrPSc allotype and disease phenotype in MV1 + 2C sCJD
Previous studies have shown that efficient transmission
of CJD into transgenic mice is influenced by the neuro-
pathological subtype of CJD as well as by whether or not
the inoculated mice express PrPC-M129 and/or PrPC-
V129 [1, 2, 5, 9, 13, 23, 44]. Four different CJD subtypes
were represented in the samples tested. We therefore
analyzed whether, within a given CJD subtype, PrPSc-
M129 was potentially influencing transmission into tg66
and tgRM mice. Since only a single case of MV2C was
available (Table 2), this subtype was not included in the
analysis.
Sporadic CJD subtype MV1 + 2C, which is neuro-
pathologically similar to MM1 sCJD [33], was repre-
sented by two cases that differed significantly in the
amount of PrPSc-M129 present (Table 2). Case 3, where
PrPSc-M129 represented 100% of the total PrPSc, caused
clinical disease when inoculated into both tg66 and
tgRM mice with incubation times indistinguishable from
that of MM1 sCJD (Table 2 and Fig. 1a). Case 4, where
PrPSc-M129 represented only 34% of the total PrPSc, did
not cause clinical disease in either mouse strain (Table 2
and Fig. 1a). It was possible that the slightly higher seed-
ing activity of case 3 (Table 1) accounted for its shorter
incubation time and higher disease transmissibility.
However, since cases 3 and 4 were classified as the same
histopathological subtype [28], the starting seeding activ-
ity or titer should not influence the final neuropatho-
logical profile and pattern of PrPSc deposition. We
therefore analyzed the neuropathological features of
both cases following transmission into transgenic mice.
Fig. 1 Survival curves for tg66 and tgRM mice inoculated with MV heterozygous CJD brain homogenate containing variable levels of PrPSc-M129.
Survival curves for mice inoculated with (a) MV1 + 2C or (b) MV2K + 2C sCJD. The percentage of PrPSc-M129 for each case inoculated is shown in
parentheses to the right of the case number. Solid lines = tg66 mice; dashed lines = tgRM mice. Survival curves for (c) tg66 or (d) tgRM mice
inoculated with MV2K CJD. The percentage of PrPSc-M129 for each case inoculated is shown in parentheses to the right of the case number.
Solid lines = sCJD cases; dashed lines = iCJD cases
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In general, the neuropathological features were similar
in both tg66 and tgRM mice (Supplementary Table 1),
and only results from tg66 mice are shown for most of
the CJD subtypes inoculated.
Spongiform change was present in the hippocampus
and granular layer of the cerebellum and was more se-
vere in the cortex in mice inoculated with case 4 when
compared to case 3, which had less extensive vacuol-
ation in the cortex and no spongiform change apparent
in either the cerebellum or hippocampus (Fig. 5a). In
terms of PrPSc deposition, diffuse, punctate/synaptic
PrPSc was deposited in mice inoculated with both cases
(Fig. 5b), but only case 4 had occasional plaque-like de-
posits as well as dense PrPSc deposits in the hippocam-
pus and granular layer of the cerebellum (Fig. 5b). In
addition, both cases were clearly neuropathologically dis-
tinct from MM1 sCJD which was characterized by mild
to moderate spongiform change and diffuse, synaptic/
punctate deposition of PrPSc in both mouse lines. (Sup-
plementary Table 1, Supplementary Fig. 1 and Fig. 2).
Thus, the data suggest that the prions in cases 3 and 4
have distinct properties that differ not only from each
other but also from the MM1 subtype of CJD prions to
which they are neuropathologically similar [33]. Our
data show a lack of consistency in transmission proper-
ties of cases of MV1 + 2C sCJD where the abundance of
PrPSc-M129 is significantly different and suggest that
there is greater phenotypic variability within this CJD
subtype than has been previously recognized.
PrPSc allotype and disease in MV2K sporadic and
iatrogenic CJD
We next analyzed whether the PrPSc allotype ratio corre-
lated with the transmission properties of the 5 cases of
Fig. 2 Lack of correlation between PrPSc-M129 or total PrPSc abundance versus disease incubation time in transgenic mice inoculated with MV
heterozygous CJD brain homogenate. a The y-axis shows the percentage of total PrPSc which is PrPSc-M129 versus disease incubation time in
days post-infection (DPI) for tg66 (left panel) and tgRM (right panel) mice. Mean + SD is shown for each CJD sample (closed circles) and the MM1
sCJD control (open circle). The results of the linear regression analysis are represented by the line and the R2 value is given in the lower left
corner of each graph. b The y-axis shows the spectral count (SpC) of the total PrPSc in the sample versus disease incubation times in DPI for tg66
(left panel) and tgRM (right panel) mice. Figure legend and linear regression analysis are the same as in panel a
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MV2K inoculated. The two sporadic CJD MV2K cases,
which contained similar levels of PrPSc-M129 (Table 2),
caused clinical disease with similar incubation times in
all of the tg66 mice (Table 2, Fig. 1c) and the majority of
tgRM mice inoculated (Table 2, Fig. 1d). Pathologically,
the two cases were indistinguishable and were character-
ized by mild to moderate spongiform change in both
mouse strains particularly in the thalamus and corpus
callosum (Supplementary Table 1, Fig. 6a). PrPSc depos-
ition was characterized mainly by a mix of perivacuolar
PrPSc and scattered PrPSc amyloid plaques in many areas
of the brain including very large plaques in the corpus
callosum (Fig. 7a).
The other three MV2K samples inoculated were hu-
man growth hormone-related cases of iatrogenic
CJD from the UK. Unexpectedly, these cases differed in
their presentation from the sCJD MV2K samples inocu-
lated. Case 19, which had significantly more PrPSc-M129
than the other 4 MV2K cases (Table 2), was also the
only MV2K sample which caused clinical disease in all
tgRM and tg66 mice inoculated (Fig. 1c and d) with in-
cubation times indistinguishable from that of MM1
sCJD (Table 2). Despite the different disease incubation
times, the neuropathological features for MV2K cases 18
and 19 were similar and distinct from that of the two
sCJD MV2K cases. Mild to moderate spongiform change
was observed in most regions of the brain (Fig. 6b) and
PrPSc was deposited in a diffuse, punctate/synaptic pat-
tern (Fig. 7b) with amyloid plaques limited to the area
around the needle scar (Supplementary Fig. 3). Interest-
ingly, PrPSc deposition in case 20 differed somewhat in
that synaptic PrPSc deposition was less prominent and
plaque-like deposits were observed in multiple brain re-
gions (Fig. 7b). The combined transmission data from
the 5 MV2K samples are consistent with the possibility
that a greater abundance of PrPSc-M129 correlates with
faster disease incubation times in this CJD subtype. The
data also show that prions from sporadic versus iatro-
genic cases of MV2K have different properties, suggest-
ing that prions from iatrogenic cases of MV2K CJD are
either not derived from sporadic MV2K prions or were
altered by passage through humans.
Brain regions from a single patient which differ in PrPSc
allotype have prions with different transmission
properties
In our previous study, we found that the PrPSc allotype
ratio could differ significantly between brain regions
Fig. 3 Type 1 PrPSc accumulates in the brains of most tg66 and tgRM mice inoculated with 3 different subtypes of MV heterozygous sCJD. a
PrPSc immunoblot of tg66 mice (left panel) and tgRM mice (right panel) inoculated with either MV1 + 2C (cases 3 and 4) or MV2C (case 11) sCJD.
Type 1 PrPSc accumulates in all of the recipient mice except for those inoculated with MV2C case 11 which accumulate Type 2 PrPSc. The
numbers above the line indicate the case number while the numbers over the individual lanes represent the 3–4 brain samples that were
analyzed for each CJD subtype inoculated. b PrPSc immunoblot of tg66 mice (left panel) and tgRM mice (right panel) inoculated with MV2K + 2C
sCJD. Type 1 PrPSc accumulates in all of the recipient mice except for tg66 mice inoculated with case 9 (CC) which accumulate Type 2 PrPSc. The
numbers above the line indicate the case number while the numbers over the individual lanes represent the 2–4 brain samples that were
analyzed for each CJD subtype inoculated. Blots were developed using the mouse monoclonal anti-PrP antibody 3F4 conjugated to biotin. Lanes
marked MV1 and MV2 are from human cases of sCJD and represent the controls for Type 1 and Type 2 PrPSc, respectively. Molecular mass
markers are indicated on the right side of the figure
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within the same patient [28] and that these differences
were associated with different patterns of PrPSc depos-
ition within the brain [28]. In order to determine
whether or not the transmission properties of the prions
in these brain regions also differed, we inoculated two
different brain regions from a single MV2K + 2C patient
(case 9) into tg66 and tgRM mice. The cerebral cortex
sample from case 9 (9 CC) did not cause clinical disease
in either tg66 or tgRM mice (Table 2, Fig. 1b) even
though it had a statistically higher abundance of PrPSc-
M129 when compared to the other MV2K + 2C samples
inoculated. By contrast, a cerebellar cortex sample from
the same case (9 CbC) caused clinical disease in all tg66
mice (Table 2, Fig. 1b) and in 50% of the tgRM mice in-
oculated, even though it had a lower abundance of
PrPSc-M129 (Table 2). These results are the opposite of
those for cases 3 and 19 where significantly higher levels
of PrPSc-M129 relative to PrPSc-V129 were associated
with faster disease incubation times (Table 2). Thus, our
data suggest not only that prions in two different brain
regions from the same patient have different transmis-
sion properties but also that the abundance of PrPSc-
M129 in heterozygous cases of CJD is not a reliable pre-
dictor of disease incubation time.
Interestingly, samples 9 CC and 9 CbC also differed
neuropathologically. Spongiform change tended to be
more severe in the mice inoculated with the CbC
sample (Supplementary Table 1, Fig. 8a). In addition,
PrPSc deposition and amyloid plaques were more
prevalent in the cortex, thalamus, and hypothalamus
in the 9 CbC sample when compared to the CC sam-
ple where PrPSc was primarily found in dense, periva-
cuolar deposits (Supplementary Table 1, Fig. 8b). The
prevalence of amyloid plaques in transgenic mice in-
oculated with the cerebellar sample from case 9 is re-
flective of what was observed in the original human
brain tissue where plaques were prominent in cerebel-
lar tissue but not in cortical tissue [28]. The most
striking difference between the two samples was in
the septum where spongiform change and dense,
perivacuolar deposits of PrPSc were present in mice
inoculated with the CC sample but were completely
absent in mice inoculated with the CbC sample (Fig.
8a and b). The transmission and neuropathological
data together strongly suggest that, in heterozygous
cases of sCJD, prions with different infectious proper-
ties can arise in brain regions with different PrPSc
allotypes.
Fig. 4 Type 1 PrPSc accumulates in the brains of tg66 and tgRM mice inoculated with heterozygous cases of MV2K sporadic and iatrogenic CJD.
a PrPSc immunoblot of tg66 mice (left panel) and tgRM mice (right panel) inoculated with MV2K cases of sCJD. Type 1 PrPSc accumulates in all of
the recipient mice. The numbers above the line indicate the case number while the numbers over the individual lanes represent the 3–4 brain
samples that were analyzed for each CJD subtype inoculated. Lanes with no label above them are blank. b PrPSc immunoblot of tg66 mice (left
panel) and tgRM mice (right panel) inoculated with MV2K cases of iCJD. Type 1 PrPSc accumulates in all of the recipient mice. The numbers
above the line indicate the case number while the numbers over the individual lanes represent the 3–4 brain samples that were analyzed for
each CJD subtype inoculated except for case 19 where only one sample was available for the tg66 mice. Blots were developed using the mouse
monoclonal anti-PrP antibody 3F4 conjugated to biotin. Lanes marked MV1 and MV2 are from human cases of sCJD and represent the controls
for Type 1 and Type 2 PrPSc, respectively. Molecular mass markers are indicated on the right side of the figure
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A third MV2K + 2C sample was inoculated that had
different transmission properties when compared to the
two samples from case 9. Case 12 caused disease in at
least some tg66 and tgRM mice inoculated but only after
a prolonged incubation time (Table 2, Fig. 1b). Strik-
ingly, the neuropathology and PrPSc deposition induced
by the case 12 sample varied depending upon the mouse
strain. In tgRM mice, mild spongiform change was ob-
served (Supplementary Table 1, Supplementary Fig. 4a)
while diffuse PrPSc deposition was observed along with
large amyloid plaques (Supplementary Fig. 4b). By con-
trast, in the single tg66 mouse where pathology was
present, spongiform change was more extensive (Supple-
mentary Table 1, Supplementary Fig. 4b) and PrPSc was
deposited in a diffuse, synaptic pattern with no amyloid
plaques apparent (Supplementary Fig. 4b). Overall, our
data show that there can be considerable variability in
the transmission properties of MV2K + 2C prions. More-
over, they suggest prions with different transmission
properties exist even within well-defined neuropatho-
logical subtypes of CJD and that host factors other than
PrPC sequence can significantly influence the final prion
disease phenotype.
Discussion
In transgenic mice expressing only human PrPC-M129, a
mismatch at amino acid 129 in the inoculum can influ-
ence disease incubation time. Thus, the MM1 subtype of
sCJD transmits most efficiently into transgenic mice
homozygous for human PrPC-M129 [2, 5, 25, 43]. How-
ever, transmission of MV heterozygous cases of CJD can
vary by incubation time and CJD type [5, 20, 23, 25, 44].
Our hypothesis was that the variable transmission effi-
ciency of heterozygous cases of sCJD into transgenic
mice expressing human PrPC-M129 was determined by
the PrPSc allotype ratio in the sample inoculated. Our
expectation was therefore that MV heterozygous CJD
samples with statistically higher levels of PrPSc-M129
would transmit disease more efficiently into our mice
than samples where PrPSc-V129 predominated. This hy-
pothesis was supported by data from two of the sCJD
subtypes we tested, MV1 + 2C and MV2K, but did not
hold true for the MV2K + 2C subtype. In the latter sub-
type, a greater abundance of PrPSc-M129 in the sample
relative to PrPSc-V129 led to prolonged incubation times
and had a negative effect on disease transmission. Thus,
our data suggest that the relative amount of PrPSc-M129
Fig. 5 Spongiform change and PrPSc deposition differ in the brains of tg66 mice inoculated with cases of MV1 + 2C with different PrPSc allotype
ratios. a H&E staining of tg66 mice inoculated with MV1 + 2C cases 3 (183 dpi) and 4 (479 dpi). The mean percentage of PrPSc-M129 in each
sample is given under the case number. b PrPSc staining using the mouse monoclonal anti-PrP antibody 3F4 conjugated to biotin. The fields are
matched to those shown in panel a. The brain regions shown are indicated in the middle of the figure. For all panels, scale bar = 50 μm
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in cases of heterozygous CJD is not predictive of disease
incubation time even when the amino acid at codon 129
is the same in both the inoculum and host.
Earlier studies have suggested that a methionine or
valine at codon 129 influences how PrPSc is deposited
[14, 16, 21, 27, 42]. A valine at residue 129 is associated
with plaque formation and a longer clinical disease
course [21] while a methionine at residue 129 is associ-
ated with a more synaptic pattern of PrPSc deposition
and shorter clinical course [21]. Our transmission data
suggest that PrPSc allotype ratio may impact the pattern
of PrPSc deposition in a similar way. In mice inoculated
with samples consisting entirely of PrPSc-M129, PrPSc
was deposited in a diffuse, punctate/synaptic pattern
with no amyloid plaques detected. In the MV heterozy-
gous CJD cases where PrPSc-V129 was present, amyloid
plaques were detected but their prevalence and location
varied. In samples where PrPSc-V129 comprised the ma-
jority of total PrPSc, amyloid plaques and plaque-like de-
posits were more common and more widely distributed
than in samples where PrPSc-V129 represented less than
half of the total PrPSc in the samples. In these latter sam-
ples, large plaques were found almost exclusively around
the needle scar (Supplementary Fig. 3) suggesting a pos-
sible lack of spread from the site of inoculation. Thus,
we hypothesize that, in MV heterozygous cases of CJD,
plaque phenotype and plaque load may reflect the rela-
tive abundance of PrPSc-V129 present.
Fig. 6 Variable spongiform change and amyloid plaque deposition in the brains of tg66 mice inoculated with sporadic or iatrogenic cases of
MV2K CJD. a H&E staining of a tg66 mouse inoculated with MV2K sCJD case 7 (386 dpi). The black arrows indicate eosinophilic amyloid plaques.
The neuropathological features of case 10 were identical to those of case 7. b H&E staining of tg66 mice inoculated with MV2K iCJD cases 19
(185 dpi, left column) and 20 (458 dpi, right column). No eosinophilic amyloid plaques are detectable in any of the brain regions shown. The
neuropathological features of case 18 were the same as those of case 19. The mean percentage of PrPSc-M129 in each sample is given under the
case number. The brain regions shown are indicated on the left. For all panels, scale bar = 50 μm
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Support for this hypothesis was provided by the pat-
tern of PrPSc deposition in mice inoculated with two dif-
ferent brain regions from a case of MV2K + 2C. PrPSc in
the cerebellar cortex sample 9 CbC was composed pri-
marily of PrPSc-V129 and led to PrPSc amyloid plaques
as well as perivacuolar PrPSc deposition in multiple brain
regions of the recipient mice. By contrast, PrPSc in the
cerebral cortex sample 9 CC was composed primarily of
PrPSc-M129 and was associated mainly with synaptic
and perivacuolar PrPSc deposition (Fig. 8b) with dense
plaques found only around the needle scar (Supplemen-
tary Fig. 3). These findings were consistent with the pat-
tern of PrPSc deposition in the original brain material
from case 9 [28]. In that case, PrPSc-V129 was signifi-
cantly more abundant in the cerebellum where plaques
were a primary feature of PrPSc deposition while PrPSc-
M129 was significantly more abundant in the cortex
where PrPSc deposition was primarily synaptic [28].
The CC and CbC samples from case 9 led to patterns
of PrPSc deposition in mice that differed from each other
but were similar to that in the brain of the original pa-
tient. This strongly suggests that prions with distinctive
properties, i.e. prion strains, are being propagated in dif-
ferent regions of the brain. Our data are also consistent
with the fact that multiple strains of prions have been
isolated from a single brain [4, 15]. However, the long
Fig. 7 Different patterns of PrPSc deposition in the brains of tg66 mice inoculated with sporadic or iatrogenic cases of MV2K CJD. a PrPSc
deposition in a tg66 mouse inoculated with MV2K sCJD case 7 (386 dpi). The black arrows indicate PrPSc-positive amyloid plaques. The fields are
matched to those shown in Fig. 6a. PrPSc deposition in case 10 was identical to that of case 7. b PrPSc deposition in tg66 mice inoculated with
MV2K iCJD cases 19 (185 dpi, left column) and 20 (458 dpi, right column). The fields are matched to those shown in Fig. 6b. PrPSc-positive
amyloid plaques are not present but occasional plaque-like deposits of PrPSc were observed. PrPSc deposition in case 18 was the same as that of
case 19. The mean percentage of PrPSc-M129 in each sample is given under the case number. All sections were stained using the mouse
monoclonal anti-PrP antibody 3F4 conjugated to biotin. For all panels, scale bar = 50 μm
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incubation time of sCJD makes it difficult to determine
how different brain regions might give rise to different
prion strains. One possibility is that, if a single spontan-
eous misfolding event were responsible for the initiation
of sCJD, different selective pressures in the cortex versus
the cerebellum could select for different prion strains.
An alternative possibility is that more than one spontan-
eous misfolding event occurred, one in the cortex and
one in the cerebellum, each of which gave rise to differ-
ent prion strains. While admittedly speculative, the latter
scenario raises the intriguing possibility that spontan-
eous formation of PrPSc may not necessarily be a rare
event in some individuals but rather a consequence of
some other deficit in the protein folding/unfolding ma-
chinery that predisposes them to accumulating mis-
folded protein.
Previous studies have suggested that MV2K and
MV2K + 2C sCJD act similarly when transmitted into
transgenic mice expressing human PrPC-M129. How-
ever, these studies were based on the results from a
single case of each type [23]. The current study, where 3
samples of MV2K + 2C and 5 samples of MV2K CJD
were tested, suggests a more complex picture. As dis-
cussed above, we observed phenotypic variability even
within a particular CJD subtype. In the MV2K + 2C sub-
type, prions from two different brain regions of case 9
differed in their transmission phenotype while the pat-
tern of PrPSc deposition in case 12 differed between tg66
and tgRM mice (Supplementary Fig. 4). This variation in
the transmission properties of different cases of MV2K +
2C makes it difficult to compare in any meaningful way
with MV2K cases of CJD. In these latter cases, there was
variation in disease phenotype depending upon whether
they were from sporadic or iatrogenic CJD. This variabil-
ity suggests that transmission of different isolates of
MV2K and MV2K + 2C into our transgenic mice may
have led to the propagation of different prion strains.
However, further passage in mice will be needed to de-
termine whether or not the phenotypes we observed are
both stable and faithfully propagated, key characteristics
Fig. 8 Spongiform change and PrPSc deposition differ in the brains of tg66 mice inoculated with two different brain regions from a single case of
MV2K + 2C sCJD. a H&E staining of a tg66 mouse inoculated with MV2K + 2C sCJD case 9 CC (502 dpi, left column) or 9 CbC (481 dpi, right
column). The black arrows indicate eosinophilic amyloid plaques. b PrPSc deposition in a tg66 mouse inoculated with MV2K + 2C sCJD case 9 CC
(502 dpi, left column) or 9 CbC (481 dpi, right column). The black arrows indicate PrPSc-positive amyloid plaques. The fields are matched to those
shown in panel a. Sections were stained using the mouse monoclonal anti-PrP antibody 3F4 conjugated to biotin. The mean percentage of PrPSc-
M129 in each sample is given under the case number. Brain regions shown are indicated in the middle of the figure. For all panels,
scale bar = 50 μm
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of prion strains. Overall, the variability we observed
within and between subtypes that have been reported to
be very similar again suggests a more complex picture of
CJD transmission where CJD subtype, PrPSc conform-
ation, PrPSc allotype, and the host likely all contribute to
the final disease phenotype.
In the UK, the PRNP codon 129 genotype of the
cohort of iCJD patients associated with exposure to
prion-contaminated human growth hormone extracts
is primarily MV heterozygous or VV homozygous,
with only a small percentage of the patients being
MM homozygous [6, 12, 40]. This PRNP genotype
distribution is distinct from that of sCJD in the UK
[6] as well as cohorts of human growth hormone-
related iCJD in France [6] and the US [7]. Based on
these genotype differences, it has been suggested that
UK human growth hormone-related iCJD was the re-
sult of exposure to a different prion strain [6, 7] than
that responsible for human growth hormone related
iCJD in France and the US.It was further pro-
posed that either MV or VV prions were responsible
for the UK cases [39, 40], with VV2 prions consid-
ered to be the most likely source [39]. Our results
demonstrating that the transmission phenotype of
MV2K prions from sCJD and iCJD differ would seem
to argue against MV2K prions as being the source of
infection for human growth hormone-related iCJD in
the UK. Nonetheless, it’s still possible that either VV2
prions were the source of infection or that passage
through humans altered the properties of the original
infectious prions leading to an iCJD MV2K prion
strain or strains that do not recapitulate the sCJD
MV2K phenotype when inoculated into transgenic
mice over-expressing human PrPC-M129.
Conclusions
PrPSc allotype is not predictive of disease incubation
time and is not the primary determinative driver of
phenotype in heterozygous cases of CJD. However, it
does appear to correlate with the type of PrPSc depos-
ited. Thus, when PrPSc-V129 predominates, PrPSc pla-
ques are common. We further conclude that, within a
single patient brain, prions with different infectious
properties can arise in brain regions with different PrPSc
allotypes. These data may help to explain why multiple
prion strains can be isolated from a single brain. Finally,
we conclude that MV2K prions from sCJD differ from
iCJD MV2K prions, suggesting that sCJD MV2K may
not have been the source of infection in human growth
hormone related cases of iCJD in the UK. Overall, our
data demonstrate that there is more heterogeneity in the
transmission properties of CJD neurological subtypes
than has been previously described and suggest a com-
plex picture of CJD transmission where CJD subtype,
PrPSc conformation, PrPSc allotype, and the host likely
all contribute to the final disease phenotype.
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